{"id":11716,"date":"2024-10-18T07:00:00","date_gmt":"2024-10-18T05:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/"},"modified":"2024-10-18T07:00:00","modified_gmt":"2024-10-18T05:00:00","slug":"irlab-presenterar-pa-redeye-neurology-theme-event","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/","title":{"rendered":"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event"},"content":{"rendered":"
\n

G\u00f6teborg, 18 oktober 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar av Parkinsons sjukdom, meddelar idag att bolaget kommer att ge en presentation vid Redeye\u2019s 7th Annual Event on Drug Development in Neurology and Brain Diseases, i Stockholm kl 10:05 den 23 oktober 2024.<\/strong><\/p>\n<\/div>\n

\n

Kristina Torfg\u00e5rd, vd, kommer att n\u00e4rvara och presentera IRLAB vid evenemanget, som h\u00e5lls p\u00e5 Redeyes kontor, M\u00e4ster Samuelsgatan 42 i Stockholm. <\/p>\n

\u201dJag ser fram emot att presentera v\u00e5r ledande portf\u00f6lj inom Parkinsons sjukdom och v\u00e5ra senaste framsteg.\u201d, s\u00e4ger Kristina Torfg\u00e5rd, vd.<\/p>\n

Presentationen kommer att lives\u00e4ndas och IRLABs presentation g\u00e5r att se live p\u00e5 Redeyes hemsida via:\u00a0https:\/\/www.redeye.se\/events\/1016173\/redeye-theme-neurology-2<\/a>.
D\u00e4r finns ocks\u00e5 mer information om eventet.<\/p>\n<\/div>\n

\n

F\u00f6r mer information<\/strong><\/p>\n

\n

Kristina Torfg\u00e5rd, VD
Tel: +46 730 60 70 99
E-post: kristina.torfgard@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan st\u00f6rningar i hj\u00e4rnans signalsubstanser och hj\u00e4rnans sjukdomar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 balans och fallfrekvens vid Parkinson. IRL757, en substans som utvecklas f\u00f6r behandling av apati vid neurodegenerativa sjukdomar, befinner sig i Fas I. Dessutom utvecklar bolaget de tv\u00e5 prekliniska programmen IRL942 och IRL1117 mot Fas I-studier. IRLAB:s pipeline har genererats av bolagets egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k\u00a0www.irlab.se<\/a>.<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB presenterar p\u00e5 Redeye Neurology Theme Event<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, 18 oktober 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar av Parkinsons sjukdom, meddelar idag att bolaget kommer att ge en presentation vid Redeye\u2019s 7th Annual Event on Drug Development in Neurology and Brain Diseases, i Stockholm kl 10:05 den 23 oktober 2024.<\/p>\n","protected":false},"template":"","class_list":["post-11716","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB presenterar p\u00e5 Redeye Neurology Theme Event - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, 18 oktober 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar av Parkinsons sjukdom, meddelar idag att bolaget kommer att ge en presentation vid Redeye\u2019s 7th Annual Event on Drug Development in Neurology and Brain Diseases, i Stockholm kl 10:05 den 23 oktober 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/\",\"name\":\"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2024-10-18T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event - IRLAB","og_description":"G\u00f6teborg, 18 oktober 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar av Parkinsons sjukdom, meddelar idag att bolaget kommer att ge en presentation vid Redeye\u2019s 7th Annual Event on Drug Development in Neurology and Brain Diseases, i Stockholm kl 10:05 den 23 oktober 2024.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/","name":"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2024-10-18T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-neurology-theme-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB presenterar p\u00e5 Redeye Neurology Theme Event"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/11716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=11716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}